Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA uses complex statistical analyses to determine the likelihood that a fetus is carrying a disorder such as Down’s syndrome or other prenatal genetic abnormalities. The opportunity to grow IONA in Asian markets was well recognised, but the acquisition of Yourgene Bioscience will accelerate this process and, in particular, act as a springboard into China and India. Financial difficulties at its major customer in Europe is a frustration, but this will be offset by reshaping its distribution footprint via an established lab group in fiscal 2018.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Yourgene – Improves growth and lowers risk
- Published:
10 Jan 2017 -
Author:
Martin Hall -
Pages:
24
Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA uses complex statistical analyses to determine the likelihood that a fetus is carrying a disorder such as Down’s syndrome or other prenatal genetic abnormalities. The opportunity to grow IONA in Asian markets was well recognised, but the acquisition of Yourgene Bioscience will accelerate this process and, in particular, act as a springboard into China and India. Financial difficulties at its major customer in Europe is a frustration, but this will be offset by reshaping its distribution footprint via an established lab group in fiscal 2018.